Share Name Share Symbol Market Type Share ISIN Share Description
Nmc Health Plc LSE:NMC London Ordinary Share GB00B7FC0762 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1,487.00 1,485.00 1,487.50 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2,057.3 256.9 119.6 12.4 3,104

Nmc Health Share Discussion Threads

Showing 701 to 722 of 4750 messages
Chat Pages: Latest  34  33  32  31  30  29  28  27  26  25  24  23  Older
DateSubjectAuthorDiscuss
22/3/2019
12:08
Seems odd the share price is down over 3% on very little volume considering the volume yday. Worth a long?
waldo2020
22/3/2019
09:42
Big holding...think it's the high PE that's the probelm.
brain smiley
22/3/2019
09:17
Can anyone explain why the share price is falling despite a very good result at the challenging environment. The group has reiterated its positive guidance for the coming year also. The management team sound very confident with the growth prospects. All the analysts except Jeffries have got a buy recommendation with TP of Gbp 4000 plus. Can’t understand why the martlet is giving the benifit to this stock. Stuck with more than 50k shares with an average price of Gbp 3700.
johnferro1
11/3/2019
15:12
Barclays Capital reiterate OVERWEIGHT and 4500p target
aishah
08/3/2019
12:55
Tssmith..a special aura surrounding anything to do with health and currently seen at a premium..this one racing back up to a p/e of 25 even now. The future I guess. You'd think the same about renewables..nope Greencoat Wind on a p/e of just 7 off its recently announced annuals( admittedly with a bit of balance sheet messing on turbine amortisation). Health shares very much in fashion in spite of recent falls.
stewart64
08/3/2019
12:21
Support around £20. would look to see for it to hit and bounce off support before taking position. good solid company, valuation just too high
tsmith2
08/3/2019
11:17
Shares with a price to earnings of 24 have high growth expectation at such a rich valuation ( higher still yesterday)...20% growth didn't cut it or EPS of 101.5p. EPS $1.40 expected, $1.33 result.
stewart64
08/3/2019
09:48
Buying opportunities
blocker2
08/3/2019
09:43
This is fairly appalling for the simple reason that neither press or broker can satisfactorily explain why these shares are plummeting post the results.Oh you can read Jeffries but albeit the price has fallen,they’re examining the exact same data as Goldmans and others.There is the question about receivables,a concern that appears to be borne out in the rising finance charge but this price slump appears to go further than that.It seems to suggest there’s something almost untoward in the accounting.That the whole corporate strategy is wayward.The company has been bundled into a category reserved for the likes of Micro Focus.Its got a nasty feel of real manipulation which luckily pushed me to sell out of one portfolio back in the mid 30s but I still have a smallish holding elsewhere.
steeplejack
07/3/2019
18:33
Broker Comment"The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions." But then it may be time to take a contrarian view, health problems are not going to go away.
jackdaw4243
07/3/2019
17:21
Goldman’s thinks that some of the concerns identified by the market (primarily Jeffries I suppose) have been addressed in these final results.That’s not to ignore the fact that Jeffries have got this right .The shares are down from over forty quid in a little over six months.This is despite Berenberg having a target price of £54 and going on record back in November as saying the shares could be a hundred pounds 4 years hence.Barclays has it as its “pick” buy and the less said about the Investors Chronicle optimism the better.The forecast multiple is now mid 20s and despite the absence of any yield to speak of,the stock looks pretty well oversold.Its over a third down since the autumn and frankly,even the bears might be reluctant to squeeze another 10% downside out of this one to hit the £23 Jeffries TP (presuming they haven’t cut it further!). https://www.sharecast.com/news/news-and-announcements/nmc-health-hails-another-year-of-record-profits-and-earnings--3780016.html
steeplejack
07/3/2019
16:31
Anybody know where I can find broker forecasts on the back of today's results?
hiraniha
07/3/2019
15:42
They didn't beat expectations. It's a bloody tough market at the moment.
johnrxx99
07/3/2019
15:40
smartinvest what changed you mind to up you target from 20?
mdr26nlz
07/3/2019
13:05
This is what Jeffries will be crowing about-On a negative note, NMC's gross debt for 2018 rose considerably to USD1.99 billion from USD1.40 billion in 2017, though this was in line with expectations
steeplejack
07/3/2019
11:30
The market never fails to suprise me as I am surprised these have dropped so much.
dtaliadoros
07/3/2019
10:40
Looks like Jeffries are having fun giving this highly rated stock a good bashing.The figures are slightly shy of best estimates.Other brokers are unreservedly bullish for all the good its doing.
steeplejack
07/3/2019
09:29
Wow I took profit on these at 29 2 days ago and gutted to see it go over 30. Happy days just got them back for 27.70 it was profit taking on around 100k shares that tanked it by the looks of things
daneth58
07/3/2019
08:59
Good top up opportunity I think? Numbers all look good. Price drop on back of profit taking perhaps?
dtaliadoros
07/3/2019
08:30
And yet the stock is tanking today. Buy on rumour sell on news
canonyau
07/3/2019
08:25
Sometimes the market is quite childlike.
steeplejack
07/3/2019
07:32
-- The Group remains confident with the guidance previously provided for FY 2019. To reiterate:o +22-24% YoY revenue growtho +18-20% YoY EBITDA growtho Excluding impact of acquisitions completed in 2018, FY 2019 revenue growth is anticipated to be 12-13% YoY and EBITDA growth approximately 15% YoYo Year-end net-debt to EBITDA to further reduce to 2.2-2.4xo 2019 guidance does not include impact of IFRS 16 implementation or the anticipated consolidation of National Medical Care Co.Management also remains confident with the longer-term Group EBITDA margin guidance of 25%.
steeplejack
Chat Pages: Latest  34  33  32  31  30  29  28  27  26  25  24  23  Older
Your Recent History
LSE
NMC
Nmc Health
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200122 07:25:34